ClinicalTrials.gov
public full text
Public Domain
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PhI to Solid Tumors and PhII to Locally Advanced or mTNBC#861144
- A Phase 1 Study in Patients With Solid Tumors#910460
- A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors#851744
- CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors#912393
- An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors#850016
Record · ID 916709
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive